1,353 results on '"Meggendorfer, Manja"'
Search Results
2. Parallel genomic analysis from paired bone marrow and peripheral blood samples of 200 cytopenic patients
3. Genomic landscape of CCUS compared to MDS and its implications on risk prediction
4. Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis
5. Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting
6. Prognostic impact of CEBPA mutational subgroups in adult AML
7. Biallelic TET2 mutation sensitizes to 5’-azacitidine in acute myeloid leukemia
8. Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion
9. Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets
10. Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
11. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
12. TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression
13. Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia
14. AML classification in the year 2023: How to avoid a Babylonian confusion of languages
15. Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022
16. Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis
17. Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies
18. Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR
19. MDS subclassification—do we still have to count blasts?
20. Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
21. The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing
22. Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
23. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
24. How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing
25. SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase
26. Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia
27. SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis
28. Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts
29. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study
30. Overlapping features of therapy-related and de novo NPM1-mutated AML
31. Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms
32. AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
33. Genomic subtyping and therapeutic targeting of acute erythroleukemia
34. ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion
35. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia
36. Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis
37. CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk
38. Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia
39. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
40. Acute myeloid leukemia exhibiting clonal instability during treatment: Implications for measurable residual disease assessments
41. Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke
42. Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
43. A case of familial donor-derived acute myeloid leukemia with underlying pre-leukemic mutations
44. Classical meets malignant hematology: a case of acquired εγδβ-thalassemia in clonal hematopoiesis
45. A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
46. Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
47. Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)
48. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification
49. SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
50. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.